Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Continues Its Expansion With Acquisition Of PharmaSwiss

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal will add commercial infrastructure in Central and Eastern Europe and provide tax benefits.
Advertisement

Related Content

Deals Of The Week: Spectrum/Allos, Amgen/AstraZeneca, Forest/Janssen
Germany's Stada Strengthens Central, Eastern European Focus With Brand, Generic Buys
Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility
Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility
North American Buyers Turn to European Branded Generics For Growth
North American Buyers Turn to European Branded Generics For Growth
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Valeant Readies For More Expansion In 2011
Cephalon Buys Swiss Generics Firm Mepha, Talking Up Diversification

Topics

Advertisement
UsernamePublicRestriction

Register

PS071809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel